🧴 Retatrutide AQ – 24 MG / 3 mL Pen – ZPHC PHARMA

🧪 Product Type

Advanced Peptide – Triple Receptor Agonist (GLP-1 / GIP / Glucagon)

Active Ingredient: Retatrutide

Concentration: 24 MG / 3 mL

Form: Pre-filled injectable pen (aqueous solution)

Manufacturer: ZPHC PHARMA

📄 Description

Retatrutide AQ by ZPHC PHARMA is a next-generation injectable peptide therapy formulated in a ready-to-use prefilled pen, containing 24 MG of Retatrutide in 3 mL of aqueous solution. It functions as a triple receptor agonist, simultaneously targeting:

• GLP-1 (Glucagon-like peptide-1)
• GIP (Gastric inhibitory peptide)
• Glucagon receptors

This unique triple action has demonstrated promising results in metabolic research, especially in obesity management, type 2 diabetes, and energy regulation.

✅ Key Benefits

• 🔥 Powerful Fat-Burning Potential
  Increases metabolic rate and promotes lipolysis
• 🍽️ Appetite Suppression & Satiety
  Helps reduce caloric intake through central appetite regulation
• 💉 Convenient Pre-Filled Pen
  Easy and precise administration without reconstitution
• 📉 Improved Blood Glucose Control
  Enhances insulin sensitivity and lowers fasting glucose
• ⚙️ Supports Weight Management & Energy Balance
  Ideal for research involving complex metabolic disorders

⚙️ Mechanism of Action

Retatrutide mimics multiple gut-derived hormones, activating receptors involved in:

• Glucose homeostasis
• Fat metabolism
• Energy expenditure
• Appetite regulation

This synergy helps deliver comprehensive metabolic modulation in experimental models.

💉 Suggested Research Use (For Laboratory Research Only)

• Dosage: Varies based on protocol (typically once weekly)
• Administration: Subcutaneous injection via prefilled pen
• No mixing or preparation required
• Monitor for metabolic markers, appetite response, and body composition changes

⚠️ Potential Side Effects

• Nausea or mild GI discomfort (usually subsides over time)
• Headache or dizziness
• Injection site irritation
• Temporary fatigue or appetite loss

Side effects are generally dose-dependent and resolve with continued use.

🚫 Contraindications / Exclusion in Research

• History or risk of thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Severe GI disorders
• Known hypersensitivity to peptide-based therapies

🛒 Product Information

• Product Name: Retatrutide AQ
• Dosage: 30 MG in 3 mL solution
• Device: Prefilled injection pen
• Brand: ZPHC PHARMA
• Intended Use: For Research Purposes Only – Not for Human Consumption
• Storage: Refrigerate at 2°C–8°C; do not freeze
• Shipping: Available via certified research supply channels